Daily Archives: November 8, 2022
Canadian guideline for the prevention and management of cardiovascular disease in primary care.
8 Nov, 2022 | 12:37h | UTCNews Release: New one-stop guideline for cardiovascular health in Canada – Canadian Medical Association Journal
NICE Guideline | Obesity: identification, assessment and management.
8 Nov, 2022 | 12:35h | UTCRelated:
ASMBS Guidelines | Indications for metabolic and bariatric surgery.
AGA clinical practice guideline on pharmacological interventions for adults with obesity.
Guideline | Preventing obesity in midlife women.
Follow-up of the ISCHEMIA trial | Similar survival after invasive vs. conservative management of stable coronary disease.
8 Nov, 2022 | 12:32h | UTCSurvival After Invasive or Conservative Management of Stable Coronary Disease – Circulation (free for a limited period)
Original Articles:
ISCHEMIA Trial: Initial Invasive vs. Conservative Strategy for Stable Coronary Disease
ISCHEMIA Trial: Management of Coronary Disease in Patients with Advanced Kidney Disease
See also:
Commentary on Twitter
#OriginalResearch simpub #AHA2022 #CIRCAHA22: From the #ISCHEMIA-EXTEND study – No difference in all-cause mortality between initial invasive vs conservative strategy but ⬇️ risk of CV mortality and ⬆️ risk of non-CV mortality w/ initial invasive strat… https://t.co/XwFS1KO02z pic.twitter.com/SG2z4D3lzY
— Circulation (@CircAHA) November 6, 2022
RCT | In patients with paroxysmal, untreated AF, cryoballoon ablation reduced recurrence compared to drug therapy.
8 Nov, 2022 | 12:29h | UTCProgression of Atrial Fibrillation after Cryoablation or Drug Therapy – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Initial treatment of paroxysmal atrial fibrillation with cryoballoon ablation was associated with a lower incidence of persistent atrial tachyarrhythmias over 3 years than rhythm-control medications. #AHA22 https://t.co/ZjLkt9L2xr pic.twitter.com/tzRiDPBSdx
— NEJM (@NEJM) November 7, 2022
RCT | Surgery reduced major adverse limb events vs. endovascular therapy in patients with chronic limb-threatening ischemia.
8 Nov, 2022 | 12:34h | UTCSurgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Bypass surgery favorable for initial treatment of chronic limb-threatening ischemia – National Institutes of Health
Commentary on Twitter
In a randomized trial of patients with limb ischemia, those assigned to bypass surgery as compared with endovascular therapy as an initial strategy had fewer adverse limb events or all-cause death at a median of 2.7 years. #AHA22 https://t.co/GePo1ss1ar pic.twitter.com/bmH56dMkHP
— NEJM (@NEJM) November 7, 2022
Phase 2 RCT | Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease.
8 Nov, 2022 | 12:30h | UTCSmall Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Lipoprotein(a) is similar to LDL cholesterol but contains apolipoprotein(a). A trial tested the effects of an oligonucleotide drug targeting apo(a) mRNA on lipoprotein(a) concentrations in patients with CVD. #AHA22 https://t.co/eLgnrnTm5D pic.twitter.com/QmNUcxeJwX
— NEJM (@NEJM) November 6, 2022
RCT | New defibrillation strategies increased the rates of survival to hospital discharge in patients with refractory ventricular fibrillation.
8 Nov, 2022 | 12:27h | UTCDefibrillation Strategies for Refractory Ventricular Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: “Double shock” from two defibrillators could save more lives – Heart & Stroke
Commentary on Twitter
In a trial involving patients with refractory ventricular fibrillation, double sequential external defibrillation or vector-change defibrillation improved survival as compared with standard defibrillation. #AHA22 https://t.co/2l2t9iGnwq pic.twitter.com/SzVU93OsrX
— NEJM (@NEJM) November 6, 2022
RCT | Rapid up-titration of guideline-directed medical therapies for acute heart failure reduced readmissions and deaths.
8 Nov, 2022 | 12:24h | UTCSafety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial – The Lancet (free registration required)
News Release: Maximizing heart failure meds within 2 weeks reduced risk of hospital readmission, death – American Heart Association
Commentary: STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends – TCTMD
Guideline | Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients.
8 Nov, 2022 | 12:21h | UTC
Guideline | Antibiotic prophylaxis for tube thoracostomy placement in trauma.
8 Nov, 2022 | 12:19h | UTC
Review | Management of heart failure with reduced ejection fraction.
8 Nov, 2022 | 12:17h | UTCManagement of heart failure with reduced ejection fraction – Heart
Review | Intravenous fluid therapy in patients with severe acute pancreatitis admitted to the intensive care unit.
8 Nov, 2022 | 12:15h | UTCRelated:
Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis – New England Journal of Medicine (link to abstract – $ for full-text)
Acute Pancreatitis: Diagnosis and Treatment – Drugs
Evidence-Based Disposition of Acute Pancreatitis – emDocs
Pancreatitis – National Institute for Health and Care Excellence
RCT | After an out-of-hospital cardiac arrest, fever prevention for 36 vs. 72 hours resulted in similar outcomes.
8 Nov, 2022 | 12:23h | UTCDuration of Device-Based Fever Prevention after Cardiac Arrest – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this trial involving patients after out-of-hospital cardiac arrest, fever prevention for 36 or 72 hours did not result in different percentages of patients dying or having severe disability or coma. #AHA22 https://t.co/Cx6x4RfqCE pic.twitter.com/vGSb0iVISN
— NEJM (@NEJM) November 6, 2022
RCT | Efficacy of a targeted-release formulation of budesonide for treating primary immunoglobulin A nephropathy.
8 Nov, 2022 | 12:14h | UTCCommentary: Oral Steroid Safely Treats IgA Nephropathy: Trial Published – Medscape (free registration required)
Commentary on Twitter (thread – click for more)
Published! (Months after being FDA approved) by @IgAN_JBarratt et al
The phase 3A part of targeted release budesonide (called Nefecon) in IgA https://t.co/weF2dZ2Efg
They included IgA with proteinuria > 1g and GFR 35 to 90 + max supported RASi
see how that worked out:
— Swapnil Hiremath, MD (@hswapnil) October 19, 2022
RCT | Precuneus magnetic stimulation for Alzheimer’s disease.
8 Nov, 2022 | 12:12h | UTCPrecuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial – Brain
Commentary: Novel Approach to TMS May Slow Cognitive Decline in Alzheimer’s – Medscape (free registration required)
Commentary on Twitter
In a randomized, double-blind, phase II trial, Koch et al. find that 24 weeks of repetitive transcranial magnetic stimulation of the precuneus slows down cognitive and functional decline in patients with Alzheimer’s disease. https://t.co/jODfVG3GAJ pic.twitter.com/p9ncGTfS7J
— Brain (@Brain1878) October 27, 2022
Single-arm P2 study | Neoadjuvant relatlimab and nivolumab in resectable melanoma.
8 Nov, 2022 | 12:11h | UTCNeoadjuvant relatlimab and nivolumab in resectable melanoma – Nature
News Release: Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma – MD Anderson News Release
Commentary on Twitter
In a phase II trial of neoadjuvant & adjuvant nivolumab+relatlimab in 30 pts with stage III or oligometastatic stage IV melanoma, the pCR rate was 57%, with a 70% pRR; 1- & 2-yr RFS was 100% & 92% vs 88% & 55% for pts with vs without any path. response: https://t.co/2ypNeUTpwb
— NatureRevClinOncol (@NatRevClinOncol) November 1, 2022
Review | Targeted temperature management in postresuscitation care after incorporating results of the TTM2 Trial.
8 Nov, 2022 | 12:09h | UTCRelated:
Temperature Control After In-Hospital Cardiac Arrest: A Randomized Clinical Trial – Circulation
Hypothermic versus Normothermic Temperature Control after Cardiac Arrest – NEJM Evidence
ERC-ESICM guidelines on temperature control after cardiac arrest in adults – Intensive Care Medicine (if the link is paywalled, try this one)
Cohort Study | Association of obesity with disease outcome in multiple sclerosis.
8 Nov, 2022 | 12:07h | UTCNews Release: Obesity at MS diagnosis linked to higher current and subsequent levels of disability – BMJ
Commentary: Obesity Linked to Greater Disability, Poorer Outcomes in MS – HealthDay
RCT | Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen.
8 Nov, 2022 | 12:06h | UTCEffects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial – Journal of Allergy and Clinical Immunology (link to abstract – $ for full-text)
News Release: Monoclonal antibody improves cat allergen immunotherapy – National Institutes of Health
RCT | Efficacy of an eye-tracking-based dichoptic home treatment for amblyopia.
8 Nov, 2022 | 12:04h | UTC
Review | Oral anticoagulant use in patients with atrial fibrillation and chronic kidney disease.
8 Nov, 2022 | 12:02h | UTC
SR | Efficacy and safety of stereotactic body radiotherapy for painful bone metastases.
8 Nov, 2022 | 12:00h | UTC
M-A | Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis.
8 Nov, 2022 | 11:58h | UTC
SR | Pregnancy after living kidney donation.
8 Nov, 2022 | 11:56h | UTCVideo: Pregnancy after living kidney donation, a review of the available evidence and current guidance
Cohort Study | Menstrual cycle regularity and length across the reproductive lifespan and risk of cardiovascular disease.
8 Nov, 2022 | 11:54h | UTCCommentary: Irregular, Long Menstrual Cycles Up Risk for Cardiovascular Disease – HealthDay
Commentary on Twitter
Irregular and long menstrual cycles across a woman’s reproductive lifespan may identify women with a higher risk of cardiovascular disease, even after accounting for established CVD risk factors. #OAResearch #OAWeek https://t.co/BxNveNAqg5
— JAMA Network Open (@JAMANetworkOpen) October 29, 2022